Phosphodiesterase 10A inhibitor

Details Phosphodiesterase 10A inhibitor Phosphodiesterase 10A inhibitor

2007-10-31

2010-12-07

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07846942

ABSTRACT:
A phosphodiesterase 10A inhibitor serving as an effective prophylactic or therapeutic agent for Parkinson's disease, Huntington's disease, Alzheimer's disease, and schizophrenia.The PDE10A inhibitor contains as an active ingredient a pyrazolo[1,5-a]pyridine derivative represented by the following general formula:wherein R1and R2are each independently a hydrogen atom or a lower alkyl group having 1 to 4 carbons; and R3is a hydrogen atom, a lower alkyl group having 1 to 4 carbons, or a lower alkoxyl group having 1 to 3 carbons.

REFERENCES:
patent: 6265577 (2001-07-01), Kouno et al.
patent: 2-131424 (1990-05-01), None
patent: 11-302190 (1999-11-01), None
patent: 2000-224992 (2000-08-01), None
patent: 00/09127 (2000-02-01), None
patent: 01/24781 (2001-04-01), None
patent: 01/40226 (2001-06-01), None
Weishaar et al., Journal of medicinal chemistry, (May 1985) vol. 28, No. 5, pp. 537-545. Ref: 102.
Souness et al., Biochemical pharmacology, 1999, vol. 58, pp. 991-999.
Suzumura et al., Brain Research, 1999, vol. 837, pp. 203-212.
Kishi et al., Journal of cardiovascular pharmacology, 2000, vol. 36, pp. 65-70.
“Inhibitory Effect of Ibudilast (KC-404) on Cyclic Nucreotide Phosphodiesterases”, Seiko Murashima: Mie Prefectural College of Nursing, et al., (Jpn Pharmacol Ther) vol. 26, No. 1 (1998), 41-45.
“Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone” John E. Souness et al., Br.J. Pharmacol. (1994) 111, 1081-1088.
“Ibudilast Modulates Platelet-Endothelium Interaction Mainly Through Cyclic GMP-Dependent Mechanism”, Journal of Cardiovascular Pharmacology 36(1) pp. 65-70 (2000), Kishi, Y. et al.
“Drug for improvement of Brain Circulation and Metabolism, and How to Use It”, Hirotoshi Kasahara, et al., Clinica, 1990, 17 (5), pp. 256-262.
Reimund et al., Biochemical and biophysical research communications, vol. 288, pp. 427-434, 2001.
Souness et al., Biochemical pharmacology, vol. 58, pp. 991-999, 1999.
Suzumura et al., Brain Research, vol. 837, pp. 203-212, 1999.
Kishi et al., Journal of cardiovascular pharmacology, vol. 36, pp. 65-70, 2000.
Supplementary European Search Report of Aug. 21, 2008 issued in connection with the European application corresponding to the present US application.
Iwasaki K. et al., “Ibudilast Improved the Memory Disturbances and Hippocampal Apoptosis in Now-Transgenic Animal Model of Alzheimer's Disease,” Society For Neuroscience Abstract Viewer and Itinerary Planner, vol. 2002; Abstract No. 685.6, XP002492918, 2002.
The Merck Manual (Japanese Edition): 17thEdition, Mark H. Beers et al. 1999, pp. 1400-1405.

Affiliated with

Also associated with

Rating

Phosphodiesterase 10A inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphodiesterase 10A inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase 10A inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4152364